Haven't had much time lately? Here's what you may have missed in the last few weeks.
Sign-up to receive the OncologyPRO alert every 2 weeks.
Overview of the Diagnosis and Treatment of GI NETs by C. Toumpanakis
Urothelial Cell Cancer by A. van der Veldt
20 Sep 2018
The anti-angiogenesis agent pazopanib has shown preliminary activity against a range of lesions in patients with the genetic disorder von Hippel-Lindau...
19 Sep 2018
Preliminary results suggest atezolizumab might be a feasible treatment for metastatic triple-negative breast cancer
18 Sep 2018
Fatal toxic events have been characterised for patients using treatments targeting CTLA-4, PD-1 or PD-L1
17 Sep 2018
Preliminary findings suggest that a combination of trabectedin and olaparib may be feasible for patients with soft-tissue sarcoma that has progressed...
14 Sep 2018
The programmed cell death protein 1 inhibitor camrelizumab may have promise as a monotherapy for patients with previously treated recurrent nasopharyngeal...
Most of oestrogen receptor positive metastatic breast cancer patients are receiving CDK4/6 inhibitors, now approved for first-line treatment. Violetta Serra explains that the challenge is now to identify resistance to these drugs in order to establish potential second line treatments.
14-15 Sep 2018, Paris, France
01-03 Sep 2018, Oxford, United Kingdom
20-23 Jun 2018, Barcelona, Spain
15-20 Jun 2018, Belgrade, Serbia
22-23 May 2018, Zurich, Switzerland
18-19 May 2018, Valencia, Spain
11-12 May 2018, Lugano, Switzerland
04-05 May 2018, Lugano, Switzerland
27-29 Apr 2018, Lugano, Switzerland
18-22 Apr 2018, Mexico City, Mexico
16-17 Apr 2018, Lugano, Switzerland
13-14 Apr 2018, Lugano, Switzerland
11-14 Apr 2018, Geneva, Switzerland
06-07 Apr 2018, Dubai, United Arab Emirates
24-29 Mar 2018, Nauen OT Groß Behnitz (Berlin area), Germany
